Entera Bio Ltd. (NASDAQ:ENTX) Short Interest Down 13.7% in March

Entera Bio Ltd. (NASDAQ:ENTX) was the target of a large decrease in short interest in the month of March. As of March 15th, there was short interest totalling 86,100 shares, a decrease of 13.7% from the February 28th total of 99,800 shares. Approximately 0.3% of the shares of the stock are sold short. Based on an average daily volume of 114,700 shares, the days-to-cover ratio is presently 0.8 days.

Institutional Trading of Entera Bio

A number of institutional investors have recently bought and sold shares of the stock. Perigon Wealth Management LLC bought a new position in Entera Bio during the fourth quarter valued at $325,000. Northern Trust Corp bought a new stake in shares of Entera Bio in the 4th quarter worth about $450,000. Parkman Healthcare Partners LLC boosted its stake in shares of Entera Bio by 2.4% during the 3rd quarter. Parkman Healthcare Partners LLC now owns 411,076 shares of the company’s stock worth $781,000 after purchasing an additional 9,558 shares during the period. Finally, Knoll Capital Management LLC grew its holdings in Entera Bio by 51.5% during the 4th quarter. Knoll Capital Management LLC now owns 5,881,879 shares of the company’s stock valued at $12,470,000 after purchasing an additional 2,000,000 shares during the last quarter. 14.11% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and set a $10.00 target price on shares of Entera Bio in a research report on Tuesday, March 18th.

Entera Bio Price Performance

Shares of Entera Bio stock traded up $0.04 during trading hours on Wednesday, reaching $1.67. The company’s stock had a trading volume of 4,157 shares, compared to its average volume of 109,820. Entera Bio has a one year low of $1.41 and a one year high of $3.35. The firm has a 50 day moving average price of $2.11 and a 200-day moving average price of $2.02. The stock has a market cap of $59.58 million, a P/E ratio of -6.40 and a beta of 1.62.

Entera Bio (NASDAQ:ENTX) last issued its quarterly earnings data on Friday, March 28th. The company reported ($0.06) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.02. The company had revenue of $0.04 million for the quarter, compared to analysts’ expectations of $0.04 million. As a group, sell-side analysts forecast that Entera Bio will post -0.28 EPS for the current fiscal year.

About Entera Bio

Entera Bio Ltd., a clinical-stage company, focuses on the development and commercialization of orally delivered peptide and protein therapeutics for unmet medical needs. The company's product candidates include the EB612, which is in Phase II clinical trials for the treatment of hypoparathyroidism; and EB613 that has completed Phase II clinical trials for the treatment of osteoporosis, as well as is in Phase I clinical trials for the treatment of stress fractures.